|
Glenmark Pharmaceuticals Ltd.
|
Income Statement
|
|
|
You can view the
Income Statement
for the last 5 years.
|
Market Cap. (Rs.)
|
52458.31 Cr.
|
P/BV
|
6.21
|
Book Value (Rs.)
|
299.28
|
|
52 Week High/Low (Rs.)
|
1843/1272
|
FV/ML
|
1/1
|
P/E(X)
|
50.10
|
|
Bookclosure
|
27/09/2024
|
EPS (Rs.)
|
37.10
|
Div Yield (%)
|
0.13
|
|
(Rs. in Crs.)
| Months | 12 | 12 | 12 | 12 | 12 |
| Source Of Info (AR = Annual Report, PR = Press Release) | PR | AR | AR | AR | AR |
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| | | | | | |
| | | | | | |
| INCOME | | | | | |
| Revenue From Operations [Net] | 13145.84 | 11813.10 | 12725.43 | 12174.20 | 10806.03 |
| Other Operating Revenues | 175.90 | 0.00 | 264.68 | 130.71 | 137.90 |
| Total Operating Revenues | 13321.74 | 11813.10 | 12990.11 | 12304.90 | 10943.93 |
| | | | | | |
| Other Income | 113.72 | 839.99 | 316.79 | 166.67 | 50.22 |
| Total Revenue | 13435.46 | 12653.09 | 13306.90 | 12471.58 | 10994.15 |
| | | | | | |
| EXPENSES | | | | | |
| Cost Of Materials Consumed | 3001.27 | 3157.82 | 3593.79 | 3278.76 | 3137.81 |
| Purchase Of Stock-In Trade | 1566.00 | 1451.17 | 1268.26 | 1117.67 | 750.27 |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 74.42 | 44.99 |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -213.93 | -195.62 | -325.09 | -11.14 | -189.25 |
| Employee Benefit Expenses | 3022.06 | 2868.14 | 2780.96 | 2447.42 | 2343.71 |
| Finance Costs | 207.07 | 515.97 | 349.58 | 298.10 | 353.11 |
| Depreciation And Amortisation Expenses | 486.01 | 581.91 | 611.27 | 486.72 | 443.55 |
| Other Expenses | 3594.96 | 3336.25 | 3393.83 | 3077.48 | 2772.03 |
| Total Expenses | 11663.43 | 11715.64 | 11672.59 | 10769.42 | 9656.22 |
| | | | | | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1772.03 | 937.45 | 1634.31 | 1702.16 | 1337.93 |
| | | | | | |
| Exceptional Items | -372.82 | -900.96 | -765.85 | -260.91 | 44.55 |
| Profit/Loss Before Tax | 1399.21 | 36.50 | 868.45 | 1441.25 | 1382.48 |
| | | | | | |
| Tax Expenses-Continued Operations | | | | | |
| Current Tax | 352.07 | 1115.55 | 566.90 | 546.65 | 498.14 |
| Deferred Tax | 0.00 | 751.79 | -75.85 | -99.05 | -85.75 |
| Total Tax Expenses | 352.07 | 1867.35 | 491.05 | 447.60 | 412.39 |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1047.14 | -1830.85 | 377.40 | 993.65 | 970.09 |
| | | | | | |
| Profit/Loss From Continuing Operations | 1047.14 | -1830.85 | 377.40 | 993.65 | 970.09 |
| | | | | | |
| Profit/Loss From Discontinuing Operations | 0.00 | 397.33 | 0.00 | 0.00 | 0.00 |
| Net Profit/Loss From Discontinuing Operations | 0.00 | 397.33 | 0.00 | 0.00 | 0.00 |
| Profit/Loss For The Period | 1047.14 | -1433.52 | 377.40 | 993.65 | 970.09 |
| | | | | | |
| Minority Interest | -0.05 | -68.15 | -80.16 | -51.94 | -0.05 |
| Consolidated Profit/Loss After MI And Associates | 1047.10 | -1501.67 | 297.25 | 941.71 | 970.04 |
| | | | | | |
| OTHER INFORMATION | | | | | |
| | | | | | |
| EARNINGS PER SHARE | | | | | |
| Basic EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| Diluted EPS (Rs.) | 37.11 | -53.22 | 10.53 | 33.37 | 34.38 |
| | | | | | |
| DIVIDEND AND DIVIDEND PERCENTAGE | | | | | |
| Equity Share Dividend | 0.00 | 70.54 | 70.54 | 70.54 | 70.54 |
